How to model pharma companies?

Modeling pharma companies requires a nuanced approach due to the industry's unique characteristics. Here's a breakdown based on the most helpful WSO content:

1. Focus on Line-by-Line Drugs and Path to Peak Sales

• Line-by-Line Drug Modeling: For large pharma, you often model individual drugs, especially the key revenue drivers. This involves projecting out sales for each drug until patent expiry.
• Path to Peak Sales: Use diffusion models or decision trees to estimate the time to peak sales and the height of peak sales. A standard assumption is that peak sales occur around 5 years post-launch, but this can vary depending on the drug and market dynamics.
• Patent Expiry: After patent expiry, assume a sharp revenue decline (e.g., 80%-90%) as generics flood the market. For small molecule drugs, the terminal value is often zero post-patent expiry.

2. Valuation Considerations

• Terminal Growth Rate (TGR): For large pharma, a reasonable TGR is typically low, around 1%-2%, reflecting the mature nature of the industry and the challenges of sustaining growth due to patent cliffs and competition.
• Implied TGR for Stock Valuation: Analyzing the implied TGR can help assess whether a stock is "cheap." Compare the implied growth rate with industry norms and the company's historical performance to identify potential mispricing.

3. Key Metrics and Assumptions

• Probability of Success: For early-stage drugs, use standard probabilities (e.g., 20% for Phase 1, 40% for Phase 2, 60% for Phase 3) to adjust cash flows.
• Operating Margins: Estimate margins for each product or segment. While specific margins are rarely disclosed, you can use cost of goods sold (COGS) data for guidance.
• Strategic Value: For small or mid-cap companies, consider the likelihood of acquisition by big pharma, as this often drives valuations.

4. Best Practices

• Sensitivity Analysis: Build sensitivities around peak sales, time to peak sales, and approval probabilities to account for the high uncertainty in drug development.
• Consult Experts: For complex areas like tax implications (e.g., NOLs) or legal considerations, consult specialized lawyers or accountants.
• Use Reliable Data Sources: Tools like Evaluate Pharma or equity research reports can provide valuable insights, but always critically assess their assumptions.

By focusing on these elements, you'll be well-equipped to model pharma companies effectively and identify key drivers of value.